Platforms

Technologies

Scroll To Explore

interrogates GPCR Signaling

 

Our proprietary bioSens-AllTM platform was implemented to interrogate the signaling complexity associated with GPCR activation. It consists of a panel of 63 BRET-based biosensors each designed to follow one specific signaling event upon GPCR activation.

Applications include :

  • Signaling signature of wild-type receptors versus mutant variants in all mode of actions
  • Orthosteric and allosteric compound bias effects
  • Orphan receptor signaling signature determination (deorphanization)
  • Detection of receptor constitutive activity
  • Receptor trafficking and regulation

DTect-AllTM is a binding technology designed for the identification of every compounds interacting with the 7-transmembrane (7-TM) domain of engineered GPCRs. The corresponding FRET-based assays, developed on stable cell lines, are screened in presence of fluorescent probes that act as surrogate markers of the GPCR change of conformation.

 

Press room
Press releases